Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

PURPOSE: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest and enhances cytarabine...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Karp, Judith E., Thomas, Brian M., Greer, Jacqueline M., Sorge, Christopher, Gore, Steven D., Pratz, Keith W., Smith, B. Douglas, Flatten, Karen S., Peterson, Kevin, Schneider, Paula, Mackey, Karen, Freshwater, Tomoko, Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Gladstone, Douglas E., Showel, Margaret M., Loechner, Sabine, Parry, David A., Horowitz, Jo Ann, Isaacs, Randi, Kaufmann, Scott H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3596113/
https://ncbi.nlm.nih.gov/pubmed/23092873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2442
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky